Advisory Board

Advisory Board Member  SELENE ROSIO MANGA, MD
Takemi Fellow at Harvard School of Public Health, USA
Latin American experienced, medical doctor, infectologist, specialist in MDRTB Control and Prevention Programs in several countries like: Ukraine, Mozambique, Peru and Papua New Guinea.
International expert on evaluation and monitoring of social impact oriented projects focused on tuberculosis, and multidrug resistant tuberculosis, past Director of the Latin America Society of Pulmonary Diseases 2018-2023, I served as Consultant for two GF Projects: Identification of Risk Factor for Migrants at the Nort Border of Peru: Tumbes and Piura Year 2022, holder: OIM, and TB in Prisons Year 2021, holde5: DIB.
Manager of MDRTB program and interventions, in vulnerable populations in Peru, such as Health and Basic Nutrition Program (USAID / IDB / World Bank) in 1998, Quality in Health 2008-2010 (USAID) National Immunization Program of Millennium Challenge Corporation (USAID / MCC) in 2010, Aprende Saludable IDB 2015-1017.
Research Associate, Department of International Health, School of Public Health, Johns Hopkins University.
Expert in the evaluation of development projects in Peru, addressed to control MDRTB a specialist in staff management in complex situations such as refugee camps, displaced persons, health and humanitarian emergencies, and natural disasters.
As MD specializing in infectology and public health team leader. infectious diseases specialist, epidemiologist, scientist researcher expert on Infection control, antibiotic resistance monitoring and surveillance, Covid 19 rapid response and research, TB elimination, TB +HIV co infection control, clinical management epidemiological analysis, infectious diseases elimination, networks member with twenty-three years’ experience as a Medical Doctor

Advisory Board Member GLEN REIN, PhD
Senior Researcher with strategic corporate experience in discovering, targeting and applying new technologies and bio-actives for conception and creation of breakthrough personal care products.  Proven record in directing and conducting innovative, patented/published, cutting-edge scientific research for claims substantiation of new products. Management and leadership skills.  Strong academic background and numerous scientific publications.  Board member of several international organizations.

Advisory Board MemberJussi Hepojoki Ph.D. virology
PhD, Associate Professor and Senior Scientific Advisor. 20+ years of experience in research on areas of virology, cell biology, immune responses and development of novel diagnostics tools. Degrees in bioprocesses, biochemistry and virology. Has raised over 2.5M€ of external competitive funding for academic research, and published over 80 articles in international peer-reviewed journals (H-index 32, citations 7203 - 05/2023). Seasoned research team leader, university educator, and supervisor of doctoral theses in universities of Helsinki and Zürich. Contributing member of American Society for Microbiology, chairman of Ribozyviria and member of Arenaviridae -study groups at the International Committee on Taxonomy of Viruses, member of The Federation of European Biochemical Societies (FEBS) fellowships committee, Review Editor of Frontiers in Virology, and frequent reviewer for other scientific journals.

Advisory Board Member Satu Hepojoki Ph.D. virology
PhD, R&D Manager, and Senior Scientific Advisor. 15+ years of experience in developing medical devices, and biomedical research. Lead & project manager on many successful CD-IVD medical device commercialisations. PhD in infectious diseases (virology), MSc in genetics, BSc in animal physiology. Seasoned product development and research leader with international experience from Zürich and London. Teaching experience from medical school, including teaching lab techniques, and supervising doctoral theses. In addition to research and development, career includes roles as scientific advisor to companies, as well as quality and regulatory related matters in the medical field.​

 ... more will be listed soon to growing advisory board.